Your browser doesn't support javascript.
loading
Comparison of two labor induction regimens with intravaginal misoprostol 25 µg and adverse perinatal outcomes.
Santiago, Marcela Beraldo; Santiago, Talita Beraldo; Oliveira, Samuel Machado; Caldas, João Victor Jacomele; Araujo Júnior, Edward; Peixoto, Alberto Borges.
Affiliation
  • Santiago MB; Universidade de Uberaba, Mário Palmério University Hospital, Gynecology and Obstetrics Service - Uberaba (MG), Brazil.
  • Santiago TB; Universidade de Uberaba, Mário Palmério University Hospital, Gynecology and Obstetrics Service - Uberaba (MG), Brazil.
  • Oliveira SM; Universidade de Uberaba, Mário Palmério University Hospital, Gynecology and Obstetrics Service - Uberaba (MG), Brazil.
  • Caldas JVJ; Universidade Federal de São Paulo, Escola Paulista de Medicina, Department of Obstetrics - São Paulo (SP), Brazil.
  • Araujo Júnior E; Universidade Federal de São Paulo, Escola Paulista de Medicina, Department of Obstetrics - São Paulo (SP), Brazil.
  • Peixoto AB; Universidade Municipal de São Caetano do Sul, Discipline of Women Health - São Caetano do Sul (SP), Brazil.
Rev Assoc Med Bras (1992) ; 70(9): e20240286, 2024.
Article in En | MEDLINE | ID: mdl-39230067
ABSTRACT

OBJECTIVE:

The aim of the study was to compare two labor induction regimens (4 and 6 h), to determine predictors of successful labor induction with intravaginal misoprostol 25 µg tablets, and to evaluate the association with adverse perinatal outcomes.

METHODS:

This was a retrospective cohort study that included singleton pregnancies undergoing induction of labor with an intravaginal misoprostol 25 µg tablet between 37 and 42 weeks of gestation. The pregnant women were divided into two groups Group 1-intravaginal misoprostol 25 µg every 4 h and Group 2-intravaginal misoprostol 25 µg every 6 h.

RESULTS:

Pregnant women were divided into Group 1 (n=289) and Group 2 (n=278). Group 1 had a higher median number of intravaginal misoprostol 25 µg tablets (3.0 vs. 2.0 tablets, p<0.001), a lower prevalence of postpartum hemorrhage (7.6 vs. 32.7%, p<0.001), and a higher need for oxytocin (odds ratio [OR] 2.1, 95%CI 1.47-2.98, p<0.001) than Group 2. Models including intravaginal misoprostol 25 µg tablets every 4 and 6 h [x2(1)=23.7, OR 4.35, p<0.0001], parity [x2(3)=39.4, OR 0.59, p=0.031], and Bishop's score [x2(4)=10.8, OR 0.77, p=0.019] were the best predictors of failure of labor induction. A statistically significant difference between groups was observed between the use of the first intravaginal misoprostol 25 µg tablet at the beginning (Breslow p<0.001) and the end of the active labor phase (Long Hank p=0.002).

CONCLUSION:

Pregnant women who used intravaginal misoprostol 25 µg every 4 h had a longer time from the labor induction to the beginning of the active phase of labor and higher rates of adverse perinatal outcomes than women who used intravaginal misoprostol 25 µg every 6 h.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxytocics / Misoprostol / Labor, Induced Limits: Adult / Female / Humans / Pregnancy Language: En Journal: Rev Assoc Med Bras (1992) Year: 2024 Document type: Article Affiliation country: Brazil Country of publication: Brazil

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxytocics / Misoprostol / Labor, Induced Limits: Adult / Female / Humans / Pregnancy Language: En Journal: Rev Assoc Med Bras (1992) Year: 2024 Document type: Article Affiliation country: Brazil Country of publication: Brazil